Clinical

Dataset Information

0

A biomarker research of ‘A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "

ABSTRACT: Primary outcome(s): Association between protein in plasma at pre-treatment and progression-free survival

DISEASE(S): Colorectal Cancer

PROVIDER: 2649959 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
| S-EPMC6336001 | biostudies-literature
Unknown Ramucirumab: preclinical research and clinical development.
| S-EPMC4218907 | biostudies-literature
Unknown Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
| S-EPMC8956527 | biostudies-literature
Unknown Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma.
| S-EPMC6249592 | biostudies-literature
Unknown Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.
| S-EPMC10594013 | biostudies-literature
Clinical Translational Research of Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD)
| 2643875 | ecrin-mdr-crc
Genomics Plasma histidine as biomarker for recurrent atrial fibrillation after catheter ablation
| PRJNA1222345 | ENA
Clinical Biomarker study using cell free DNA in patients with colorectal cancer
| 2633274 | ecrin-mdr-crc
Unknown Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
| S-EPMC7670803 | biostudies-literature
Genomics Plasma miR-98-5p as a diagnostic biomarker for oxaliplatin-induced neuropathic pain related to NGF and catecholamine dysregulation
2026-02-24 | GSE319960 | GEO